The takeaway
This experimental medicine improved weight and blood-sugar measures in a diabetes trial, but many participants stopped treatment. Its development was later discontinued.
What was tested?
Researchers randomized 834 adults with overweight or obesity and type 2 diabetes taking metformin to cotadutide, liraglutide or placebo. Blood sugar and weight were coprimary outcomes at 14 weeks; secondary follow-up continued to 54 weeks. The liraglutide comparator was unblinded.
Cotadutide doses pooled; all-cause completion, not adverse-event rates
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Cotadutide, pooled | 458 / 612 (74.8%) |
| Liraglutide 1.8 mg | 103 / 110 (93.6%) |
| Placebo | 91 / 112 (81.3%) |
What changed?
At 54 weeks, the cotadutide 300 micrograms daily group had a weight reduction 4.34 percentage points greater than placebo; liraglutide 1.8 mg daily differed from placebo by 2.65 points. These are differences from placebo, not each group’s total loss or a direct between-drug difference. The later per-protocol analysis excluded participants who stopped study drug or had important protocol violations and carried the last observation forward for missing data.
Why completion matters
Treatment completion differed across groups. These figures count all causes of stopping, not just adverse events, and do not establish comparative safety. Digestive adverse events were more common with cotadutide. Unequal attrition and the unblinded comparator limit interpretation. AstraZeneca sponsored and helped conduct and report the study.
Where does it fit today?
Cotadutide is part of the history of combining hormone pathways. AstraZeneca later reported a strategic decision to discontinue development. The decision does not by itself establish either harm or universal safety.
Sources
Nahra and colleagues, Diabetes Care, 2021